In a case of consolidation in the Chinese pharma sector, LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million. Under the terms of the deal ...
The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD candidates with blockbuster potential. According to Reuters, MSD – known as Merck & Co in ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results